BioWorld6h
FDA approves GE Healthcare’s Flyrcado for CAD diagnosis
GE Healthcare Technologies Inc. received U.S. FDA approval for its novel radiotracer, Flyrcado (flurpiridaz F-18), for use in ...
WebMD9h
New Drug Promises More Accurate Diagnosis for Heart Disease
The injectable tracer, Flyrcado, could help doctors flag deadly coronary artery disease in patients during imaging tests.
GE HealthCare Stock Likely to Rise After FDA Approval of Flyrcado
GEHC's Flyrcado, a first-of-its-kind PET tracer for coronary artery disease, receives FDA approval, expanding diagnostic access and improving patient outcomes.
GE Aerospace Stock Can Rise Another 25%, Says Barclays
Barclays analyst David Strauss raised his GE Aerospace price target to $230 from $200. It’s the highest target on the Street, ...
Buy Rating for GE Healthcare on Flyrcado’s Market Potential and FDA Approval
Analyst Larry Biegelsen from Wells Fargo maintained a Buy rating on GE Healthcare Technologies Inc (GEHC – Research Report) and keeping ...
Approval of New Test Agent Lifts GE Healthcare Stock
GE HealthCare shares are up nearly 1% after getting the green light late Friday from U.S. regulators to sell a new diagnostic imaging agent that analysts say could be a big seller for the [General Ele ...
GE HealthCare’s Flyrcado PET radiotracer secures FDA approval
It is expected to improve access to PET MPI, particularly for patients who are challenging to image, such as those with a ...
US FDA approves GE HealthCare's diagnostic drug for heart disease
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery ...